Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The JointJYNT -1.22%63 EV-to-EBITDA is 45.23 as of Jul. 19, 2026, which is 5% below its 10-year median of 47.72. GuruFocus rates JYNT with a GF Score™ of 63/100 and a GF Value™ of $11.21 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 507 Healthcare Providers & Services companies, The Joint ranks worse than 89.35% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, The Joint's enterprise value is $108.54 Mil.
The Joint's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $2.40 Mil. Therefore, The Joint's EV-to-EBITDA for today is 45.23.
The historical rank and industry rank for The Joint's EV-to-EBITDA or its related term are showing as below:
JYNT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -100.08 Med: 47.72 Max: 999.25
Current: 45.23
During the past 13 years, the highest EV-to-EBITDA of The Joint was 999.25. The lowest was -100.08. And the median was 47.72.
JYNT's EV-to-EBITDA is ranked worse than 89.35% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 11.1
vs JYNT: 45.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
The Joint (NAS:JYNT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The Joint's share price for today is $8.92.
The Joint's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for The Joint's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, The Joint's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Joint EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Joint's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where The Joint's EV-to-EBITDA falls into.
The Joint's current Enterprise Value is $108.54 Mil.
The Joint's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Joint (JYNT) has a EV-to-EBITDA of 45.23 as of Jul. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on The Joint. This is near median its historical median of 47.72. According to the industry distribution chart, The Joint ranks #453 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 89.3%.
Is The Joint's EV-to-EBITDA too high?
The Joint's current EV-to-EBITDA of 45.23 is near median its 10-year median of 47.72. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.10. The Joint's value of 45.23 is 307.5% above this industry median. Based on the distribution chart, The Joint ranks #453 out of 507 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, The Joint has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Joint's EV-to-EBITDA compare to PARK and WW?
According to the Healthcare Providers & Services industry distribution chart, The Joint ranks #453 out of 507 companies for EV-to-EBITDA. This places The Joint in the lower half of its industry. The industry median EV-to-EBITDA is 11.10. The Joint's value of 45.23 is 307.5% above this benchmark. While the company's 10-year median is 47.72 vs. the industry median of 11.10, The Joint has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.10, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Joint's current EV-to-EBITDA of 45.23 is 307.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on The Joint. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Joint's current EV-to-EBITDA is 45.23, which is near median its own 10-year median of 47.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Joint stock overvalued right now?
Based on GuruFocus' analysis, The Joint (JYNT) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.21, compared to a current price of $8.92 — trading 20.4% below its estimated fair value. The current EV-to-EBITDA is 45.23, which is near median its 10-year median of 47.72 and 307.5% above the Healthcare Providers & Services industry median of 11.10. The Joint's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For The Joint (JYNT), the current EV-to-EBITDA is 45.23 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Joint (JYNT) Overvalued in 2026?
Based on GuruFocus' analysis, The Joint stock appears to be undervalued.
The current stock price of $8.92 is trading 20.4% below its estimated GF Value™ of $11.21.
GuruFocus considers The Joint to be Modestly Undervalued.
Key valuation signals for JYNT:
EV-to-EBITDA: 45.23 (near median its 10-year median of 47.72)
GF Value™: $11.21 vs. price of $8.92 (20.4% below fair value)
Industry Position: 307.5% above the Healthcare Providers & Services median (#453 of 507)
No single metric tells the full story. See the JYNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
63GF Score
Get the complete analysis for JYNT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JYNT has been successfully added to your 
